![Marc Voigt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marc Voigt
Algemeen Directeur bij
IMMUTEP LIMITED
Vermogen: 351 850 $ op 30-09-2026
Profiel
Mr. Marc Voigt is a Chairman-Supervisory Board & President at Immutep SAS, a Chief Executive Officer & Executive Director at Immutep Ltd., a Co-Managing Director at Immutep GmbH and a Member at Pharma-Lizenz-Club Deutschland.
He is on the Board of Directors at Immutep Ltd. Mr. Voigt was previously employed as a Vice Chairman-Supervisory Board by Elanix Biotechnologies AG, a MD, Chief Operating & Financial Officer by caprotec bioanalytics GmbH, a Chief Financial Officer by Revotar Biopharmaceuticals AG, a Director-Executive Board by Allianz SE, a Principal by Allianz Versicherungs AG, a Director-Finance, Legal & Business Development by Medical Enzymes AG, and a General Manager-European Operations by Immutep GmbH.
He received his MBA from Freie Universität Berlin.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IMMUTEP LTD 1,01% | 18-03-2026 | 14.877.395 ( 1,01% ) | 351 850 $ | 30-09-2026 |
Actieve functies van Marc Voigt
| Bedrijven | Functie | Begin |
|---|---|---|
| IMMUTEP LIMITED | Algemeen Directeur | 09-07-2014 |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
Immutep SAS
 Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Voorzitter | 18-11-2015 |
Immutep GmbH
 Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Algemeen Directeur | - |
Eerdere bekende functies van Marc Voigt
| Bedrijven | Functie | Einde |
|---|---|---|
Medical Enzymes AG
 Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Financieel Directeur/CFO | 02-01-2006 |
Revotar Biopharmaceuticals AG
 Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Financieel Directeur/CFO | 02-01-2006 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Corporate Officer/Principal | - |
| ELANIX BIOTECHNOLOGIES AG | Directeur/Bestuurslid | - |
caprotec bioanalytics GmbH
 caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Financieel Directeur/CFO | - |
Opleiding van Marc Voigt
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
41
Eerstegraads connecties
11
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 11 |
|---|---|
Allianz SE
 Allianz SE Multi-Line InsuranceFinance Provides property, casualty, life and health insurance & asset management services | Finance |
Immutep Ltd.
 Immutep Ltd. BiotechnologyHealth Technology Engages in the development of anti-cancer therapeutics | Health Technology |
Elanix Biotechnologies AG
 Elanix Biotechnologies AG BiotechnologyHealth Technology Develops and commercializes products for acute wound care, dermatological, and gynecological applications | Health Technology |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Health Technology |
Allianz Versicherungs AG
 Allianz Versicherungs AG Multi-Line InsuranceFinance Provides motor, property, liability and accident insurance services | Finance |
Freie Universität Berlin
 Freie Universität Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Health Technology |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Health Services |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Health Technology |
Pharma-Lizenz-Club Deutschland | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Health Technology |
